Oncocyte Corp Changes Independent Accountant
Ticker: IMDX · Form: 8-K · Filed: Apr 17, 2025 · CIK: 1642380
Sentiment: neutral
Topics: auditor-change, accounting
TL;DR
Oncocyte swapped auditors from BDO USA to Armanino LLP, effective April 11, 2025.
AI Summary
Oncocyte Corporation announced on April 11, 2025, a change in its certifying accountant. The company has dismissed its previous independent registered public accounting firm, BDO USA, LLP, and has appointed Armanino LLP as its new principal accountant. This change is effective immediately.
Why It Matters
A change in a company's auditor can sometimes signal underlying financial concerns or a desire for a fresh perspective on financial reporting.
Risk Assessment
Risk Level: medium — Changes in auditors can sometimes precede or coincide with financial irregularities or a shift in accounting practices, warranting closer scrutiny.
Key Players & Entities
- Oncocyte Corporation (company) — Registrant
- BDO USA, LLP (company) — Former Certifying Accountant
- Armanino LLP (company) — New Certifying Accountant
- April 11, 2025 (date) — Effective date of change
FAQ
When was the change in Oncocyte Corporation's certifying accountant effective?
The change was effective as of April 11, 2025.
Who was Oncocyte Corporation's previous independent registered public accounting firm?
Oncocyte Corporation's previous independent registered public accounting firm was BDO USA, LLP.
Who has been appointed as Oncocyte Corporation's new principal accountant?
Armanino LLP has been appointed as Oncocyte Corporation's new principal accountant.
Did Oncocyte Corporation's board of directors approve this change in accountants?
The filing states that the change was approved by the Audit Committee of the Board of Directors.
Has Oncocyte Corporation had any disagreements with BDO USA, LLP that led to this change?
The filing explicitly states that there were no disagreements between Oncocyte Corporation and BDO USA, LLP.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 17, 2025 regarding Oncocyte Corp (IMDX).